WilmerHale Partner Stuart Falber has been named a "Go To Lawyer" by Massachusetts Lawyers Weekly (MLW), a new feature from the publication which showcases leaders in the Massachusetts legal community by practice area.

MLW highlighted some of Falber’s significant deals in the last few months, including his representation of Tetraphase Pharmaceuticals, a biopharma company commercializing a novel treatment for life-threatening infections, in its acquisition by La Jolla Pharmaceutical for $43 million in up-front cash and up to $16 million in potential contingent value payments. He also represented Generation Bio, a genetics medicines company creating a new class of gene therapy, in its initial public offering of more than 12 million shares of common stock. The IPO, which followed a successful $100 million round of Series C crossover financing, was noteworthy because Generation Bio was one of the first biotech companies to go public during the pandemic. In the past year, Falber represented biopharma company Alkermes in its acquisition of Rodin Therapeutics, which included a $100 million upfront cash payment and future payments of up to $850 million based on attainment of certain milestones.

Falber’s successful transactions, according to MLW, has earned him praise from clients for “bringing to the table strong resources from his firm and for leading a team of talented attorneys.”